Docetaxel

證據等級: L5

預測適應症: 10 個

Docetaxel: From Taxane Antineoplastic to Female Breast Carcinoma

One-Sentence Summary

Docetaxel is a taxane-class cytotoxic chemotherapy agent used globally for the treatment of multiple solid tumours including breast, prostate, and lung cancers, but is currently not registered in South Africa. The TxGNN model predicts it may be effective for Female Breast Carcinoma, with 50 clinical trials and 20 publications currently supporting this direction — including multiple large completed Phase 3 RCTs recognised by the FDA and EMA.

Quick Overview

Item	Content
Original Indication	No SAHPRA-registered indication (drug not currently registered in South Africa)
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.90%
Evidence Level	L1
South Africa Market Status	Not registered
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Docetaxel is a taxane-class microtubule-stabilising agent. It works by promoting tubulin polymerisation and inhibiting depolymerisation, thereby blocking tumour cells at the G2/M phase of cell division and inducing programmed cell death (apoptosis). This mechanism directly targets the machinery that all rapidly dividing cells depend on — a hallmark of breast carcinoma regardless of subtype.

Breast cancer cells — whether hormone receptor-positive, HER2-positive, or triple-negative — depend on continuous active proliferation for growth and survival. Docetaxel’s cytotoxic effect is therefore broadly applicable across breast cancer subtypes. Beyond its standalone activity, it demonstrates well-documented synergy with HER2-targeted agents (trastuzumab, pertuzumab), anthracyclines and alkylating agents (doxorubicin, cyclophosphamide), platinum salts (carboplatin), and immune checkpoint inhibitors (pembrolizumab) — making it a backbone agent across neoadjuvant, adjuvant, and metastatic treatment settings.

Docetaxel has been approved for breast cancer by both the FDA and EMA for over 30 years, with Level 1 evidence from multiple Phase 3 RCTs enrolling thousands of patients. Landmark trials such as BCIRG 005 (n=5,351), NSABP B-27 (n=2,411), HERA (n=2,168), and FNCLCC/PACS 01 (n=3,010) directly establish its clinical benefit in early and locally advanced disease, while Phase 2 and 3 data confirm its role in HER2-negative and triple-negative metastatic breast cancer. The TxGNN prediction reflects a globally established clinical reality; the primary opportunity for South Africa is establishing formal regulatory access pathways through SAHPRA.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00003782	Phase 3	Completed	5,351	Three-arm adjuvant trial comparing AC→T vs AT vs ATC in node-positive breast cancer; established Docetaxel-containing regimens as standard adjuvant care
NCT00002707	Phase 3	Completed	2,411	Preoperative AC alone vs AC + Docetaxel (pre- or postoperative) in operable Stage II–III breast cancer; pivotal neoadjuvant trial establishing pCR as a surrogate endpoint
NCT01275677	Phase 3	Completed	3,270	Adjuvant TC or AC→paclitaxel ± trastuzumab in HER2-low invasive breast cancer; large adjuvant platform assessing the role of HER2-targeted therapy addition
NCT00593697	Phase 3	Completed	2,168	Trastuzumab + Docetaxel → FEC vs same regimen → single-agent trastuzumab in HER2+ early breast cancer; evaluated disease-free survival
NCT00054587	Phase 3	Completed	3,010	Docetaxel 75 mg/m² + Epirubicin 75 mg/m² vs FEC100 in node-positive breast cancer with sequential trastuzumab in HER2+++ patients
NCT03639948	Phase 2	Active, Not Recruiting	120	Pembrolizumab + Carboplatin + Docetaxel as neoadjuvant therapy in triple-negative breast cancer (TNBC); contemporary immunochemotherapy combination
NCT00217672	Phase 2	Completed	76	Docetaxel ± Bevacizumab as first-line therapy for HER2-negative metastatic breast cancer; directly evaluated Docetaxel efficacy and the added value of anti-angiogenic therapy
NCT01352494	Phase 2	Unknown	99	Docetaxel + Gemcitabine as neoadjuvant chemotherapy in locally advanced breast cancer; multi-centre assessment of response rate and safety profile
NCT01547741	Phase 3	Unknown	1,871	Docetaxel + Cyclophosphamide (TC) vs anthracycline-based regimens in HER2-negative node-positive or high-risk node-negative breast cancer; direct comparison of non-anthracycline Docetaxel regimen
NCT05301010	Phase 3	Completed	128	Trastuzumab biosimilar (NNG-TMAB) + Docetaxel in HER2+ recurrent or metastatic breast cancer; confirmed biosimilar equivalence with Docetaxel as the chemotherapy backbone

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28398846	2017	Phase 3 RCT	J Clin Oncol	ABC Trials (USOR 06-090, NSABP B-46-I/B-49): compared TC6 vs TaxAC — anthracycline-containing taxane regimens superior to TC6 in reducing early breast cancer recurrence
7595719	1995	Review	J Clin Oncol	Comprehensive review of Docetaxel’s preclinical and clinical pharmacology; foundational reference establishing antineoplastic mechanism and early clinical activity in breast cancer
26874836	2017	Cohort	Breast Cancer (Tokyo)	Docetaxel + Cyclophosphamide + Trastuzumab (HER-TC) as neoadjuvant chemotherapy in HER2+ breast cancer; reported pCR rates with hormone receptor subtype stratification
9282422	1997	Review	Drug Ther Bull	Comparative review of paclitaxel and docetaxel in breast and ovarian cancer; contextualised early evidence for the taxane class in breast carcinoma
12599222	2003	Phase 2	Cancer	Capecitabine + Docetaxel + Epirubicin (TEX) as first-line treatment in locally advanced or metastatic breast carcinoma; demonstrated clinical activity in a triplet regimen
11481357	2001	Phase 2 RCT	J Clin Oncol	Dose-dense Doxorubicin + Docetaxel ± Tamoxifen as preoperative therapy in operable breast cancer; randomised evaluation of pathological complete response rates
15585076	2004	Phase 2	Clin Breast Cancer	Docetaxel + Cisplatin as primary (neoadjuvant) chemotherapy in locally advanced breast cancer; evaluated pCR and down-staging rates prior to modified radical mastectomy
9364543	1997	Phase 2	Oncology	Docetaxel + Vinorelbine combination in metastatic breast cancer and NSCLC; reported response rates of 23–36% in previously untreated patients
19856651	2009	Phase 1	Tumori	Docetaxel + Gemcitabine dose-finding study in anthracycline-pretreated metastatic breast cancer; established feasibility of weekly scheduling
27997437	2017	Cohort	Anti-Cancer Drugs	Association between adjuvant Docetaxel-based chemotherapy and breast cancer-related lymphedema; identified risk factors relevant to patient monitoring in clinical practice

South Africa Market Information

Docetaxel currently has no SAHPRA registrations and is not marketed in South Africa.

Healthcare professionals requiring access to Docetaxel must apply for Section 21 unregistered medicine authorisation from SAHPRA on a patient-by-patient or programme basis. This is a significant access barrier, given that the drug is a standard-of-care agent internationally.

There are no registered products to list at this time.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Taxane class (microtubule-stabilising agent)
Myelosuppression Risk	High — febrile neutropenia is the dose-limiting toxicity; Grade 3/4 neutropenia occurs in 75–85% of patients receiving standard 3-weekly Docetaxel 75 mg/m²; G-CSF prophylaxis is strongly recommended
Emetogenicity Classification	Low to moderate (MASCC/ESMO classification: minimal to low emetogenic potential for Docetaxel monotherapy; increases to moderate when combined with anthracyclines or platinum)
Monitoring Items	Full blood count (FBC) with differential before each cycle; liver function tests (ALT, AST, alkaline phosphatase, total bilirubin — Docetaxel is contraindicated with significant hepatic impairment); peripheral neuropathy assessment; fluid retention and oedema monitoring (cumulative dose-related; corticosteroid premedication required)
Handling Protection	Must be prepared and administered according to cytotoxic drug handling regulations — closed-system transfer devices (CSTD), appropriate PPE (gloves, gown, eye protection), dedicated pharmacy laminar-flow preparation area, and cytotoxic waste disposal per South African regulations

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for complete safety information once registration is obtained. In the interim, consult the FDA or EMA-approved prescribing information (Taxotere® US Prescribing Information / EU SmPC) for full details on warnings, contraindications, and drug interactions.

Report any adverse drug reactions experienced during Section 21 access to SAHPRA via the MedSafety pharmacovigilance reporting system.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Docetaxel has one of the strongest evidence bases in oncology for female breast carcinoma, with multiple completed Phase 3 RCTs (each enrolling 2,000–5,000 patients) and longstanding FDA and EMA approvals. The evidence quality meets L1 criteria. The primary barriers to use in South Africa are the complete absence of SAHPRA registration and the associated safety data gaps — these are administrative and regulatory challenges, not clinical or scientific ones.

To proceed, the following is needed:

Immediate access: Apply for SAHPRA Section 21 unregistered medicine authorisation for individual patients requiring Docetaxel, supported by clinical justification and global prescribing information
Medium-term registration: Initiate or support a full SAHPRA marketing authorisation application using the existing FDA/EMA-approved dossier as the basis (abridged registration pathway)
Safety documentation: Obtain the FDA or EMA-approved Professional Information (PI/SmPC) to complete the contraindications, key warnings, and drug interaction profile review (resolving Data Gaps DG001 and DG002)
Pharmacy and infrastructure readiness: Confirm cytotoxic drug preparation infrastructure (CSTD-equipped pharmacy units) and cold-chain logistics at treating institutions
Clinical protocols: Develop G-CSF prophylaxis protocols for febrile neutropenia management appropriate to South African oncology practice settings, and establish corticosteroid premedication schedules for fluid retention prevention
Pharmacovigilance: Register Docetaxel use under Section 21 with SAHPRA MedSafety to enable adverse event tracking prior to full registration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.